Halozyme Therapeutics Inc (HALO) vs peers

$125.63

Latest weekly close · Market cap $15.2B

HALO's P/E is 36.6x, compared with 29.0x at the middle of 6 peers.

Peer group: Biotechnology. Updated .

HALO and Biotechnology, ranked by P/E
StockP/EOwn 5-year percentile
HALOHalozyme Therapeutics Inc36.6×97
ABBVAbbVie80.6×76
BIIBBiogen44.8×100
VRTXVertex Pharmaceuticals30.6×80
AMGNAmgen27.4×78
REGNRegeneron Pharmaceuticals19.9×67
INCYIncyte14.7×5
GILDGilead Sciencesn/an/a, not ranked
MRNAModernan/an/a, not ranked
Peer median29.0×
How to read this comparison

Up to eight covered companies in the same industry, largest market value first.

P/E divides the share price by earnings per share over the last twelve months. The peer median leaves out HALO and stocks without a reading.

Each percentile compares a stock with its own weekly readings over the last five years, so 20 means its P/E is above 20% of its own past readings. It needs at least 26 weeks of history. It is not a rank against the other stocks in this table.

Different growth rates, margins and financial risks can explain different multiples. Stocks without positive earnings have no reading.

HALO versus the peer median

+26%

HALO
36.6×
Peer median
29.0×
Own 5-year median
18.9×

Source: SEC company filings and weekly market prices. Multiples use the last twelve months of financial results. Updated .

How the valuation data is built